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Although there is still some resistance to the evidence-based medicine movement, evidence-
based health care has now become 
widely accepted and adopted. Systematic 
reviews of the effectiveness of health 
care interventions are the engine room 
of evidence-based health care; much has 
been written about how these reviews 
should be conducted and what they can 
achieve [1,2]. If the case for the use of 
systematic reviews is good in developed 
countries—and we think it is—then the 
case is even stronger in the developing 
world. Wherever health care is provided 
and used, it is essential to know which 
interventions work, which do not work, 
and which are likely to be harmful. This 
is especially important in situations 
where health problems are severe and 
the scarcity of resources makes it vital 
that they are not wasted [3].
But are the systematic reviews that 
have so far been published relevant and 
of practical use to those who provide 
health care in “the majority world” 
(i.e., in developing countries? In our 
view, the relevance of systematic reviews 
to frontline health care workers in 
developing countries has so far been 
limited, for a number of reasons.
Reasons Why the Relevance 
Is Limited
Conditions. Most of the reviews 
produced to date address health 
conditions that are priorities in the 
developed world [4]. Many major 
health concerns in developing nations 
have yet to be made the subject of 
a review, although there are signs 
that this may be changing [5]. The 
introductory discussions of most reviews 
focus on the impact of conditions in 
the United States and Western Europe. 
This may be an indication of the 
authors’ own priorities and experience, 
or it may be because they have made 
assumptions about the priorities of 
journal editors and readers. 
Interventions. Health care 
professionals in developing countries 
sometimes wonder whether their 
reliance on older, cheaper, “lower-
tech” approaches has made their 
practice quite distinct from that of their 
colleagues in richer regions [6]. Yet 
the authors of systematic reviews seem, 
by and large, to prefer to take on the 
task of assessing the evidence for more 
recent (and generally more expensive) 
technologies. This is not to say that 
reviewers should avoid high-tech 
interventions. Again, it is a question of 
setting priorities, and of recognising 
the urgent need for more reviews on 
interventions that are feasible in the 
majority world.
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Exclusion of studies from the 
developing world. Systematic reviews 
are based largely on research that has 
been done in rich countries. One of 
the reasons for this is the relative lack 
of research in developing countries. 
However, even when research has 
been conducted in these countries, 
it might not be published [7]—or if 
it is published, it might not be in a 
journal that is indexed in the widely 
used bibliographic databases such as 
MEDLINE and EMBASE. Thus, despite 
the best efforts of many reviewers, 
relevant studies may easily be missed. 
Excluding studies on the basis of 
language or region is generally not 
considered good practice in systematic 
reviewing [8], but the difﬁ culties of 
identifying and assessing such studies 
can make ﬁ nding them and including 
them in a review an unrealistic 
expectation. 
Quality of studies from the 
developing world. Once studies have 
been found, they are assessed for 
quality by the reviewers. Only when 
the quality meets the criteria speciﬁ ed 
in the review protocol (in most cases, 
this speciﬁ es randomised controlled 
trials only) are they included in the 
analysis. The difﬁ culties of conducting 
randomized controlled trials in 
resource-poor situations result in the 
exclusion of many developing country 
studies. Some have suggested that the 
“quality threshold” should be lowered, 
so that more studies from developing 
countries can be included in systematic 
reviews. This question is contentious, 
and indeed divides the authors of this 
essay, but it needs to be recognised and 
debated openly.
Transferability. Practitioners in 
low-income countries have questioned 
the “transferability” of evidence 
derived from studies conducted in 
richer nations [9]. The basis of their 
concern is their awareness that there 
can be many differences between 
patient populations and in the 
delivery of health care. Forjuoh et 
al. have pointed out that some injury 
prevention interventions will have 
broad transferability, while others 
will not [10]. They went on to make 
suggestions as to which intervention 
would be transferable, but they did so 
on theoretical grounds without any 
supporting data. 
Features of the typical health care 
experience of a patient living in the 
developing world, as compared with 
features of the typical health care 
experience of a patient in a clinical trial 
in a developed country, are shown in 
Box 1.
There are also important differences 
in the way in which care is delivered in 
developing and developed countries. 
In developing countries, treatments 
that would be delivered by doctors 
elsewhere are often delivered by 
medical assistants or clinical ofﬁ cers. 
This may or may not have an impact 
on the effectiveness of the treatment. 
Similarly, legislation can be considered 
a health care intervention for the 
prevention of road trafﬁ c injury, but 
the “delivery” of such legislation (i.e., 
its enforcement) is often harder to 
achieve in developing countries for a 
multitude of reasons. 
As a result of such differences, 
the most effective treatment in a 
randomised controlled trial may not 
be the most effective treatment when 
provided in the developing world. 
Some treatments will retain much of 
their effectiveness in a resource-poor 
context; others will not. 
One recently updated Cochrane 
review on the primary repair of 
penetrating colon injuries is a case 
in point [11]. The update involved 
the addition of data from one study, 
which had been completed since the 
original version of the review had been 
published. This addition introduced 
a much greater level of heterogeneity.  
The likely explanation for this, in the 
opinion of the reviewers, was that the 
new study was the only one in which 
the intervention had been applied in a 
developing country, which had imposed 
a number of limitations on its delivery. 
Rather than implying that a 
review’s conclusions are globally 
applicable, perhaps this is one of those 
circumstances where it would be more 
appropriate if reviewers concluded with 
statements such as, “There is evidence 
for the effectiveness of this intervention 
in the countries and setting where the 
included studies were conducted, and 
in places that are similar in terms of the 
resources available.”
What Can Be Done?
It is, of course, vital that more research 
of quality and relevance is conducted 
in developing countries, but the writers 
of systematic reviewers also have much 
to do. We need to ﬁ nd ways to make a 
good product better, and we must do 
more to make sure that people in the 
majority world are able to access the 
reviews that are published. In order 
for progress to be made, the following 
questions require more attention than 
they have received up to now.
Authors. How can we involve more 
people from developing countries 
in the writing and peer reviewing of 
systematic reviews? For example, how 
can we continue to build on progress 
made on international activity within 
the Cochrane Collaboration [12] (see 
Table 1)?
Titles. How can we get more reviews 
written on (a) health problems that 
are priorities, and (b) interventions 
that are affordable and feasible in the 
majority world?
Context. Should reviews focus on 
speciﬁ c contexts in relation to the 
location of the condition and the 
delivery of the intervention?
Background sections. How can 
we encourage reviewers to look at 
conditions/interventions globally, and 
not just as they affect the United States 
and Western Europe?
Box 1. Comparison of the 
Health Care Experiences of 
Patients in the Less Developed 
and Developed Worlds
Features of the typical health care 
experience of a patient living in the less 
developed world include
• late presentation
• self-medication of “prescription” drugs 
or traditional treatments 
• poor facilities may delay diagnosis
• referral (if needed) not easily arranged 
• if a child, may be malnourished
• if a woman, may be anaemic
• will experience problems because 
of shortages of trained staff
• …and because of poor infection 
control
• …and because of a lack of follow-up 
care
• patient may be unable (e.g., because 
of lack of funds) to fully adhere to 
treatment.
Features of the typical health care 
experience of a patient in a clinical trial in 
a developed country include
• none of the above
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Search for studies. How can we make 
it easier to ﬁ nd and review data from 
research done in developing countries?
Analysis. Should reviewers be 
encouraged to consider whether 
heterogeneity between study results 
might be due to differences in 
underlying resources?
Conclusions. Should conclusions 
address whether any recommendations 
apply everywhere, or just in settings 
similar to those in which the included 
studies were done? Or is this beyond 
the recommendations of a review?
Dissemination of the ﬁ ndings of 
reviews. Is this best done by circulating 
the reviews themselves, or are reviews 
merely a stage in the production of 
more accessible evidence-based health 
information materials? For example, 
the World Health Organization’s 
Reproductive Health Library, available 
on CD-ROM, includes selected 
Cochrane reviews but also summaries 
and commentaries that have been 
specially prepared to provide a 
developing world perspective. The 
BMJ’s Clinical Evidence produces 
other summaries of the evidence (for 
example, often integrating the ﬁ ndings 
of Cochrane Reviews into answers to 
clinical questions), and aims to prepare 
these in user-friendly formats and 
languages. Are more initiatives like 
these needed?
Research. Research is needed on 
the impact of systematic reviews on 
practice in the developing world. We 
need to assess: What proportion of 
reviews are relevant to health care in 
low-resource settings? Are evidence-
based sources used to set policy in 
different countries? How widely 
are the Cochrane Library and/or 
Cochrane reviews used by health care 
workers, and what are the barriers to 
use? How widely are these resources 
used by other people involved in 
decisions about health care, including 
patients, their carers, and policy 
makers? Has the use of Cochrane 
evidence inﬂ uenced practice? What do 
these users and potential users think 
would make reviews more useful? 
Conclusion
When so-called developing countries 
ﬁ rst gained freedom from their 
colonial oppressors, Ernst Schumacher 
pointed out that there was a need, 
not for the “best” technology, but for 
“appropriate” technology [13]. When 
it comes to health care, practitioners 
and patients of these countries need 
and deserve nothing less than the most 
“appropriate evidence”. 
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